Thomas Baumgartner, Giovanni Di Liberto, Valentin Loser, Alex Vicino, Marie Théaudin, Mayté Castro-Jiménez, Cécile Alexandra Hübsch, Julien Bally, Jean-Michel Pignat, Arseny A Sokolov, Davide Strambo, Lorenz Hirt, Patrik Michel, Olivier Rouaud, Gilles Allali, Jan Novy, Andrea Rossetti, Philippe Ryvlin, Raphaël Bernard-Valnet, Caroline Pot Kreis, Renaud Du Pasquier
{"title":"[Neurology: what's new in 2024].","authors":"Thomas Baumgartner, Giovanni Di Liberto, Valentin Loser, Alex Vicino, Marie Théaudin, Mayté Castro-Jiménez, Cécile Alexandra Hübsch, Julien Bally, Jean-Michel Pignat, Arseny A Sokolov, Davide Strambo, Lorenz Hirt, Patrik Michel, Olivier Rouaud, Gilles Allali, Jan Novy, Andrea Rossetti, Philippe Ryvlin, Raphaël Bernard-Valnet, Caroline Pot Kreis, Renaud Du Pasquier","doi":"10.53738/REVMED.2025.21.900-1.59","DOIUrl":null,"url":null,"abstract":"<p><p>In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for Parkinson's disease has been proposed, while a neuroprosthesis is improving gait in advanced stages. Revised criteria for inclusion body myositis and multiple sclerosis are refining diagnoses, and blood biomarkers are enabling early detection of Alzheimer's disease. The effectiveness of early thrombolysis in stroke has been confirmed, and new treatments are being explored for cerebral hemorrhages. In epilepsy, surgery reduces mortality by 30% in drug-resistant patients. Finally, new treatments targeting PACAP and CGRP are reducing refractory migraines with good tolerability.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 900-1","pages":"59-62"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2025.21.900-1.59","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for Parkinson's disease has been proposed, while a neuroprosthesis is improving gait in advanced stages. Revised criteria for inclusion body myositis and multiple sclerosis are refining diagnoses, and blood biomarkers are enabling early detection of Alzheimer's disease. The effectiveness of early thrombolysis in stroke has been confirmed, and new treatments are being explored for cerebral hemorrhages. In epilepsy, surgery reduces mortality by 30% in drug-resistant patients. Finally, new treatments targeting PACAP and CGRP are reducing refractory migraines with good tolerability.
期刊介绍：
Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
